阿托伐他汀早期强化治疗对急性冠脉综合征患者血浆Lp—PLA2和hs—CRP的早期影响(2)
![]() |
第1页 |
参见附件。
此外,两组患者血脂监测结果显示,与治疗前相比,血脂水平均无明显降低,提示Lp-PLA2和hs-CRP水平降低与阿托伐他汀降血脂作用无关。本研究中两组患者在用药过程中均未出现明显肝、肾功能损伤、乏力、肌痛、肌酸激酶异常升高等他汀类药物相关不良反应,提示无论早期强化治疗还是常规治疗,短期应用均是安全的。
总之,本研究结果证实阿托伐他汀早期强化治疗ACS患者可发挥其强大的抗炎症作用,明显降低血浆Lp-PLA2和hs-CRP水平。但本研究患者人数偏小,有待进一步的临床观察。
参考文献:
[1] Lewandowski M, Kornacewicz-Jach Z, Millo B, Zielonka J, Czechowska M, Kaliszczak R, P?ońska E, Goracy J, Ka?mierczak J, Naruszewicz M. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J. 2008;15(4):357-64.
[2] 马颖霞,赵爱昌,陈传欣,等.急性冠脉综合征患者血小板膜糖蛋白Ⅱb/Ⅲa的变化.心脑血管病防治.2002,2(2):26-27.
[3] Pabon OP ,Nieto BF,Morinigo MJ.et al. The effect of the mean platelet volume on the short-term prognosis of acute myocardial infarct [J] .Revista Espahola de Cardiologia.1998,51(10):816-822.
[4] Ridker PM, Danielson E, Fonacca, FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med,2008,359:2195—2207.
[5] Aikawa M, Rabkin E, Sugiyama S, et al. An HMG - CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metallo - proteinases and tissue factor in vivo and in vitro. Circulation. 2001, 103: 276 -283.
[6] Bourcier T, Libby P.HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000, 20: 556 - 562.
您现在查看是摘要介绍页,详见PDF附件。